Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 3/20 | 0.35 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.33 |
| ▸ | TNKS | O95271 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081931 | 0.86 | TNKS2 (0.34) | TNKS2TNKSGAAMAPTPARP2 | |
| SCHEMBL16631520 | 0.85 | SMPD3 (0.38) | SLC9A1SMPD3TNKS2TNKSGAA | |
| SCHEMBL16631519 | 0.82 | TNKS (0.35) | TNKS2TNKSGAAMAPTPARP2 | |
| SCHEMBL16631454 | 0.81 | TNKS (0.34) | TNKS2TNKSGAAMAPTPARP2 | |
| SCHEMBL18080471 | 0.81 | TRPV1 (0.37) | SLC9A1SMPD3GAAMAPT | |
| SCHEMBL16631450 | 0.79 | MAPT (0.38) | SLC9A1SMPD3GAAMAPTALOX5 | |
| SCHEMBL16631412 | 0.76 | TNKS2 (0.39) | TNKS2TNKSGAAMAPTPARP2 | |
| SCHEMBL18081755 | 0.75 | HPGD (0.36) | TNKS2TNKSGAAMAPTPARP2 | |
| SCHEMBL18081954 | 0.72 | NPC1 (0.33) | SLC9A1 | |
| SCHEMBL16631364 | 0.72 | MGAM (0.35) | TNKS2TNKSGAAPARP2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | SLC9A1 4215/4885SMPD3 1349/4885TNKS2 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.